Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling

INTRODUCTION: Crizotinib is an oral multitargeted tyrosine kinase inhibitor (TKI) with activity against lung cancers driven by ALK-rearrangements, ROS1-rearrangements and MET-amplification. Comprehensive genomic profiling (CGP) based on clinical next generation sequencing (NGS) can detect crizotinib...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Lung Cancer
Main Authors: Le, Xiuning, Freed, Jason A., VanderLaan, Paul A., Huberman, Mark S., Rangachari, Deepa, Jorge, Susan E., Lucena-Araujo, Antonio R., Kobayashi, Susumu S., Balasubramanian, Sohail, He, Jie, Chudnovksy, Yakov, Miller, Vincent A., Ali, Siraj M., Costa, Daniel B.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418215/
https://ncbi.nlm.nih.gov/pubmed/25922291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.002
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki